MX2010003230A - Metodos para la sintesis de ciertos compuestos de acido hidroxamico. - Google Patents

Metodos para la sintesis de ciertos compuestos de acido hidroxamico.

Info

Publication number
MX2010003230A
MX2010003230A MX2010003230A MX2010003230A MX2010003230A MX 2010003230 A MX2010003230 A MX 2010003230A MX 2010003230 A MX2010003230 A MX 2010003230A MX 2010003230 A MX2010003230 A MX 2010003230A MX 2010003230 A MX2010003230 A MX 2010003230A
Authority
MX
Mexico
Prior art keywords
synthesis
hydroxamic acid
methods
optional purification
carboxylic acid
Prior art date
Application number
MX2010003230A
Other languages
English (en)
Spanish (es)
Inventor
Helge A Reisch
Peter Leeming
Prasad S Raje
Original Assignee
Topotarget Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget Uk Ltd filed Critical Topotarget Uk Ltd
Publication of MX2010003230A publication Critical patent/MX2010003230A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2010003230A 2007-09-25 2008-09-23 Metodos para la sintesis de ciertos compuestos de acido hidroxamico. MX2010003230A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97488007P 2007-09-25 2007-09-25
PCT/GB2008/003226 WO2009040517A2 (en) 2007-09-25 2008-09-23 Methods of synthesis of certain hydroxamic acid compounds

Publications (1)

Publication Number Publication Date
MX2010003230A true MX2010003230A (es) 2010-04-07

Family

ID=40293778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003230A MX2010003230A (es) 2007-09-25 2008-09-23 Metodos para la sintesis de ciertos compuestos de acido hidroxamico.

Country Status (7)

Country Link
US (1) US8642809B2 (enExample)
EP (1) EP2203421B1 (enExample)
JP (1) JP2010540426A (enExample)
CN (1) CN101868446A (enExample)
CA (1) CA2700173C (enExample)
MX (1) MX2010003230A (enExample)
WO (1) WO2009040517A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CA2748813C (en) 2009-01-09 2018-07-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2451790A4 (en) * 2009-07-07 2012-12-26 Anthem Biosciences Private Ltd INHIBITORS OF HISTONE DEACETYLASE
BR112013000414A2 (pt) 2010-07-07 2016-05-17 Univ Texas compostos proneurogênicos
CN102531972A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 抗肿瘤药物Belinostat的中间体的制备方法
CN102786448B (zh) * 2012-08-09 2014-03-12 深圳万乐药业有限公司 一种合成belinostat的方法
WO2014031986A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
CN103724239A (zh) * 2013-12-31 2014-04-16 无锡万全医药技术有限公司 一种3-（3-苯基氨磺酰基-苯基）-丙烯酸酯的制备方法
CN103787924A (zh) * 2014-01-14 2014-05-14 北京万全德众医药生物技术有限公司 抗肿瘤药物Belinostat的一种新纯化方法
CN104478769B (zh) * 2014-12-22 2016-01-06 深圳万乐药业有限公司 一种适合工业化生产的贝利司他合成方法
CN105367455B (zh) * 2015-12-18 2017-10-24 深圳万乐药业有限公司 一种贝利司他异构体的制备方法
MY199967A (en) 2016-03-15 2023-11-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP7082263B2 (ja) 2016-03-15 2022-06-08 オリソン ヘノミクス エセ． アー． 造血器悪性腫瘍の治療のための、ｌｓｄ１阻害剤の組合せ
US20190256459A1 (en) * 2016-05-17 2019-08-22 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of belinostat
WO2018020406A1 (en) 2016-07-26 2018-02-01 Fresenius Kabi Oncology Ltd Polymorphic forms of belinostat and processes for preparation thereof
WO2018029699A1 (en) * 2016-08-11 2018-02-15 Msn Research & Development Center Solid state forms of (2e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide and process for preparation thereof
CN106565552A (zh) * 2016-10-31 2017-04-19 瑞阳制药有限公司 贝利司他结晶体及其制备方法
CA3082972C (en) * 2017-11-27 2022-10-11 Council Of Scientific & Industrial Research Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors
CN108033902B (zh) * 2017-12-26 2020-07-07 深圳万乐药业有限公司 一种高纯度贝利司他顺式异构体的制备方法
CN109265377B (zh) * 2018-10-25 2021-01-22 瑞阳制药股份有限公司 贝利司他的绿色合成方法
CN109336788A (zh) * 2018-10-31 2019-02-15 安徽省庆云医药股份有限公司 一种贝利司他的制备方法
CN111848591B (zh) * 2019-04-25 2022-03-18 成都先导药物开发股份有限公司 Hdac抑制剂及其制备方法和用途
CN115636774B (zh) * 2022-12-01 2023-12-22 南开大学 一种贝利司他的合成方法
CN119456224B (zh) * 2024-10-31 2025-11-28 郑州大学 一种矿物的预处理方法协同浮选药剂的分离工艺

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
EP0827742A1 (en) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
CZ20011342A3 (cs) * 1998-10-13 2001-09-12 Fujisawa Pharmaceutical Co., Ltd. Cyklické tetrapeptidy
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
KR20020070285A (ko) * 1999-11-23 2002-09-05 메틸진, 인크. 히스톤 디아세틸라제의 억제제
JP4975941B2 (ja) * 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
US20050119305A1 (en) * 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
ES2310213T3 (es) 2001-05-02 2009-01-01 The Regents Of The University Of California Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa.
IL160253A0 (en) * 2001-08-09 2004-07-25 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
CA2457043A1 (en) 2001-08-21 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
CN100377706C (zh) * 2002-01-11 2008-04-02 马蒂亚斯·拉特 包含多酚的营养药物制剂及在制备治疗癌症药物中的用途
WO2003066579A2 (en) 2002-02-07 2003-08-14 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
US20050288227A1 (en) * 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
CN1720034A (zh) * 2002-03-04 2006-01-11 艾顿药物公司 诱导末期分化的方法
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
ES2322950T3 (es) 2002-03-13 2009-07-02 Janssen Pharmaceutica Nv Derivados de aminocarbonilo como nuevos inhibidores de histona-desacetilasa.
AU2003229883B2 (en) 2002-04-03 2009-06-11 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
AU2003219595A1 (en) * 2002-04-11 2003-10-27 In2Gen Co., Ltd. Alpha,Beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
DE10233412A1 (de) 2002-07-23 2004-02-12 4Sc Ag Neue Verbindungen als Histondeacetylase-Inhibitoren
KR20050034732A (ko) 2002-08-02 2005-04-14 아젠터 디스커버리 리미티드 히스톤 디아세틸라제 억제제로서의 치환된티에닐-히드록사믹산
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
TW200418806A (en) 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
AU2003900608A0 (en) 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
JP2006518219A (ja) 2003-02-18 2006-08-10 マックスサイト インコーポレーティッド 電気穿孔法による細胞への抗原の負荷方法
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
TW200424187A (en) 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
US7276612B2 (en) 2003-04-07 2007-10-02 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
CA2525251C (en) 2003-05-09 2015-10-27 Duke University Cd20-specific antibodies and methods employing same
US20070123580A1 (en) 2003-05-21 2007-05-31 Atadja Peter W Combination of histone deacetylase inhibitors with chemotherapeutic agents
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
KR100924737B1 (ko) * 2003-08-26 2009-11-04 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｄａｃ 억제제를 이용한 암의 치료 방법
CN101856348A (zh) 2003-08-29 2010-10-13 斯隆-凯特林癌症研究所 联合治疗癌症的方法
US20070110719A1 (en) * 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
US20060270016A1 (en) * 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
US20070009956A1 (en) 2003-12-30 2007-01-11 Council Of Scientific And Industrial Research Arginine hydrochloride enhances chaperone-like activity of alpha crystallin
GB0401876D0 (en) * 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
ATE437370T1 (de) * 2004-02-27 2009-08-15 Us Gov Health & Human Serv Pharmakodynamische tests mit durchflusszytometrie
DK1591109T3 (da) * 2004-04-30 2008-10-06 Topotarget Germany Ag Formulering, der omfatter histondeacetylaseinhibitorer, der udviser tofaset frigivelse
DK1781321T3 (da) 2004-08-02 2014-04-14 Zenyth Operations Pty Ltd Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist
WO2006014024A1 (ja) * 2004-08-06 2006-02-09 Ono Pharmaceutical Co., Ltd. 精神神経系疾患治療剤
CA2576667A1 (en) * 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
JP5435871B2 (ja) * 2004-12-31 2014-03-05 ホルム，ペル・ゾンネ Ｅ１−マイナスアデノウイルス及びその使用
US20090036435A1 (en) * 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
NZ589276A (en) * 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
CA2606598C (en) * 2005-05-13 2014-12-23 Topotarget Uk Limited Pharmaceutical formulations of hdac inhibitors
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
WO2007024574A2 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
TW200800872A (en) * 2005-09-07 2008-01-01 Plexxikon Inc PPAR active compounds
WO2007049262A1 (en) 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
JP5377968B2 (ja) * 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
AU2007217562A1 (en) * 2006-02-22 2007-08-30 4Sc Ag Indolopyridines as EG5 kinesin modulators
CN101389628B (zh) * 2006-02-22 2013-02-27 4Sc股份公司 作为eg5驱动蛋白调节剂的吲哚并吡啶
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
EP2026805A1 (en) * 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8338482B2 (en) * 2006-07-20 2012-12-25 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
EP2099443A4 (en) * 2006-11-10 2010-05-05 Syndax Pharmaceuticals Inc ASSOCIATION OF ERA + LIGANDS AND HISTONE DEACETYLASE INHIBITORS IN THE TREATMENT OF CANCER
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008090534A1 (en) 2007-01-26 2008-07-31 Berand Limited Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity
US7915245B2 (en) * 2007-02-01 2011-03-29 The Board Of Regents Of The University Of Texas System Methods and compositions of trail-death receptor agonists/activators
WO2008101121A2 (en) * 2007-02-14 2008-08-21 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by muc1 and klf proteins
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
EP2167090A4 (en) * 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8637554B2 (en) * 2008-05-07 2014-01-28 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Also Published As

Publication number Publication date
CN101868446A (zh) 2010-10-20
EP2203421B1 (en) 2014-05-07
JP2010540426A (ja) 2010-12-24
WO2009040517A3 (en) 2009-06-25
CA2700173C (en) 2016-10-11
US20100286279A1 (en) 2010-11-11
EP2203421A2 (en) 2010-07-07
US8642809B2 (en) 2014-02-04
HK1145831A1 (en) 2011-05-06
WO2009040517A2 (en) 2009-04-02
CA2700173A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
MX2010003230A (es) Metodos para la sintesis de ciertos compuestos de acido hidroxamico.
EA201071058A1 (ru) Получение леналидомида
EA201170168A1 (ru) Комплекс (минерал-аминокислота)-полисахарид
NO20082783L (no) Induserbare ekspresjonssystemer
FR2929271B1 (fr) Procede pour la preparation du 1,2,3,3,3-pentafluoropropene- 1
BR112014015909A8 (pt) composição
EP3329919A8 (en) Acc inhibitors and uses thereof
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
UA106586C2 (uk) Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
EA201490132A1 (ru) Противовирусные соединения
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
EA201190144A1 (ru) Изотиазолилоксифениламидины и их применение в качестве фунгицидов
CL2009000503A1 (es) Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida.
CL2012000374A1 (es) Metodo para la preparacion de una composicion saborizante activa que comprende una primera reaccion entre un compuesto amino y un carbonilo, resultando una primera mezcla de intermediarios, una segunda reaccion con un segundo compuesto amino solo o en combinacion con un compuesto carbinilo, resultando una segunda mezcla de intermediarios, reacciones serparadas adicionales con compuestos de otras clases quimicas, ultima reaccion que comprende una mezcla de todas las mezclas de intermediarios anteriores.
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
EA201400124A1 (ru) Крупномасштабное производство станнсопорфина высокой чистоты
BRPI0606814A2 (pt) processo para a polimerização de monÈmeros contendo vinila
NO20091990L (no) Substituerte pyrazoler, sammensetninger inneholdende disse, fremgangsmate for fremstilling og anvendelse
CY1108156T1 (el) Στερεοεκλεκτικη συνθεση αναλογων βιταμινης d
ATE540026T1 (de) Hydroxyphenylsulfonsäureamide als antiapoptotische bcl-inhibitoren
BR112014012078A2 (pt) método de preparação de uma espuma
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
WO2012145638A3 (en) Self-tanning compositions having reduced maillard reaction malodor

Legal Events

Date Code Title Description
FG Grant or registration